Overall, we have identified a new and improved inducer for myeloid differentiation in HL-60 cells by suitably modifying the 3,4-dihydroxy phenyl part of 1, with the 5-nitrofuran group, which can be further developed as a potential drug targeting inducer of C/EBPα expression for leukemia treatment. The gene discussed is CEBPA; the disease is leukemia.